Placebo-Controlled Trials of Covid-19 Vaccines — Why We Still Need Them

We can address important Covid-19 control needs with continued follow-up of placebo recipients in phase 3 vaccine trials, use of placebo controls in large, simple safety trials, and clinical data from randomized trials evaluating new vaccines.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2021-01, Vol.384 (2), p.e2-e2, Article 2
Hauptverfasser:	Krause, Philip R., Fleming, Thomas R., Longini, Ira M., Peto, Richard, Beral, Valerie, Bhargava, Balram, Cravioto, Alejandro, Cramer, Jakob P., Ellenberg, Susan S., Figueroa, J. Peter, Halloran, Elizabeth, Henao-Restrepo, Ana M., Ryan, Michael J., Levine, Myron M., Nason, Martha, Nohynek, Hanna M., Plotkin, Stanley, Rees, Helen, Singh, Jerome A., Swaminathan, Soumya
Format:	Artikel
Sprache:	eng
Schlagworte:	Clinical decision making Clinical trials Coronaviruses COVID-19 COVID-19 Vaccines Decision making General & Internal Medicine Humans Immunization Life Sciences & Biomedicine Medicine, General & Internal Pandemics Placebos Public health Randomized Controlled Trials as Topic Science & Technology Severe acute respiratory syndrome coronavirus 2 Vaccines
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	We can address important Covid-19 control needs with continued follow-up of placebo recipients in phase 3 vaccine trials, use of placebo controls in large, simple safety trials, and clinical data from randomized trials evaluating new vaccines.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMp2033538